RESEARKA

Real tension: the useful signal is narrower than the topic label. The lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction.

Citation Support

• source_1 Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
• source_2 Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL
• source_3 Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients
• source_4 Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
• source_5 Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML